Product Candidate
Discovery
PRECLIN
PHASE 1
PHASE 2
PHASE 3
MARKET
Status
HCVProtease Inhibitor
glecaprevir-containing combo* (MAVYRET™)
Pan-genotypic: Marketed by AbbVie
RSVN-protein Inhibitor
EDP-938
Phase 2
NASHFXR Agonist
EDP-305
Phase 2 "ARGON-1" study
PBCFXR Agonist
EDP-305
Phase 2 "INTREPID" study
HBVCore Inhibitor
EDP-514
Phase 1
NASHFXR Agonist follow-on
Preclinical
NASHUndisclosed
Preclinical

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed as MAVYRET (U.S.) and MAVIRET (ex-U.S.), it replaces VIEKIRA PAK (no longer sold in the U.S.) and VIEKIRAX (sold primarily in select jurisdictions where MAVIRET is not yet approved).